References
- Landers M, Dorsey R, Saria S. Digital endpoints: definition, benefits, and Current barriers in accelerating development and adoption. Digit Biomarkers. 2021;5(3):216–223. doi: 10.1159/000517885
- Prasad EM, Hung S-Y. Current therapies in clinical trials of Parkinson’s disease: a 2021 update. Pharmaceuticals (Basel). 2021 Jul;14(8). doi: 10.3390/ph14080717
- Marra C, Chen JL, Coravos A, et al. Quantifying the use of connected digital products in clinical research. NPJ Digit Med. 2020;3(1):50. doi: 10.1038/s41746-020-0259-x
- Al Meslamani AZ. Underreporting of adverse drug events: a look into the extent, causes, and potential solutions. Expert Opin Drug Saf. 2023 May;22(5):351–354. doi: 10.1080/14740338.2023.2224558
- Al Meslamani AZ, Kassem AB, El-Bassiouny NA, et al. An emergency plan for management of COVID-19 patients in rural areas. Int J Clin Pract. 2021 Oct;75(10):e14563. doi: 10.1111/ijcp.14563
- Faisal S, Ivo J, Patel T. A review of features and characteristics of smart medication adherence products. Can Pharm J/Rev des Pharm du Canada. 2021 Jul;154(5):312–323. doi: 10.1177/17151635211034198
- Bian S, Zhu B, Rong G, et al. Towards wearable and implantable continuous drug monitoring: a review. J Pharm Anal. 2021;11(1):1–14. doi: 10.1016/j.jpha.2020.08.001
- Carrol G, “Drug safety and wearables,” 2018. [Online]. Available from: https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-harnessing-safety-data-from-wearable-devices.pdf
- Chung J-Y. Digital therapeutics and clinical pharmacology. Transl Clin Pharmacol. 2019 Mar;27(1):6–11. doi: 10.12793/tcp.2019.27.1.6
- Kruizinga MD, Stuurman FE, Exadaktylos, et al. Development of novel, value-based, digital endpoints for clinical trials: a structured approach toward fit-for-purpose validation. Pharmacol Rev. 2020 Oct;72(4):899–909.
- Aapro M, Bossi P, Dasari A, et al. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2020 Oct;28(10):4589–4612.
- Taylor KI, Staunton H, Lipsmeier F, et al. Outcome measures based on digital health technology sensor data: data- and patient-centric approaches. NPJ Digit Med. 2020;3(1):97. doi: 10.1038/s41746-020-0305-8
- Boehme P, Hansen A, Roubenoff R, et al. How soon will digital endpoints become a cornerstone for future drug development? Drug Discov Today. 2019 Jan;24(1):16–19
- Colloud Metcalfe S, Metcalfe, Belachew T, et al. Evolving regulatory perspectives on digital health technologies for medicinal product development. NPJ Digit Med. 2023;6(1):56. doi: 10.1038/s41746-023-00790-2
- Helwig A. Solving the barriers to digital connected care. 2022 [cited 2024 Feb 2]. Available from: https://healthcare.rti.org/insights/solving-barriers-digital-connected-care
- Bertha Alaj A, Alaj, Bousnina R, et al. Incorporating digitally derived endpoints within clinical development programs by leveraging prior work. NPJ Digit Med. 2023;6(1):139. doi: 10.1038/s41746-023-00886-9
- Gigani Y. Digital endpoints in clinical Trials; DHTS. Game changer or not?. 2022 [cited 2024 Feb 2]. Available from: https://www.lqventures.com/digital-endpoints-in-clinical-trials-dhts-game-changer-or-not/